Author:
Kalmanti Lida, ,Saussele Susanne,Lauseker Michael,Proetel Ulrike,Müller Martin C.,Hanfstein Benjamin,Schreiber Annette,Fabarius Alice,Pfirrmann Markus,Schnittger Susanne,Dengler Jolanta,Falge Christiane,Kanz Lothar,Neubauer Andreas,Stegelmann Frank,Pfreundschuh Michael,Waller Cornelius F.,Spiekermann Karsten,Krause Stefan W.,Heim Dominik,Nerl Christoph,Hossfeld Dieter K.,Kolb Hans-Jochem,Hochhaus Andreas,Hasford Joerg,Hehlmann Rüdiger,
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference49 articles.
1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Chen H, Feuer E, Cronin K, (Editors) SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations).Bethesda, MD:National Cancer Institute;2012http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 10 March 2012
2. Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, Andersson T, Hoglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18):2514–2520. doi: 10.1200/jco.2011.34.7146
3. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Müller MC, Hasford J, Heimpel H, Hehlmann R (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leuk 23(3):602–604. doi: 10.1038/leu.2008.245
4. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F, Rozman C (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63(4):789–799
5. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850–858